Selectively targeting key inflammatory pathways in cystic fibrosis-Reference-Cited by-同舟云学术

Selectively targeting key inflammatory pathways in cystic fibrosis

Published:2020-11 Issue: Volume:206 Page:112717
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Costantini Claudio^ORCID,Puccetti Matteo^ORCID,Pariano Marilena,Renga Giorgia^ORCID,Stincardini Claudia^ORCID,D’Onofrio Fiorella,Bellet Marina M.^ORCID,Cellini Barbara,Giovagnoli Stefano,Romani Luigina

Funder

Italian Cystic Fibrosis Research Foundation

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference75 articles.

1. The future of cystic fibrosis care: a global perspective;Bell;Lancet Respir Med,2020

2. Cystic fibrosis;Elborn;Lancet,2016

3. Inflammation in cystic fibrosis: an update;Roesch;Pediatr. Pulmonol.,2018

4. Inflammation in Cystic Fibrosis;Keith,2020

5. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators;Perrem;Pediatr. Pulmonol.,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Potential of N-Butyl-l-deoxynojirimycin (l-NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent;ACS Pharmacology & Translational Science;2024-05-10

2. Harnessing inter-kingdom metabolic disparities at the human-fungal interface for novel therapeutic approaches;Frontiers in Molecular Biosciences;2024-04-24

3. Dual species sphingosine-1-phosphate lyase inhibitors to combine antifungal and anti-inflammatory activities in cystic fibrosis: a feasibility study;Scientific Reports;2023-12-20

4. COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections;International Immunopharmacology;2023-04

5. Pulmonary drug delivery technology enables anakinra repurposing in cystic fibrosis;Journal of Controlled Release;2023-01